drugdeliverybusiness2h
Koru Medical inks deal to develop next-gen subcutaneous infusion system
Koru Medical Systems (Nasdaq:KRMD) announced today that it signed a development agreement with a global pharmaceutical company.
Koru announces pact for next-gen subcutaneous immunoglobulin infusion system
Systems announced the signing of an agreement with a global pharmaceutical company. The agreement is intended for KORU ...
KORU Medical Systems Announces Agreement for Next-Generation Subcutaneous Immunoglobulin Infusion System
KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on ...
Medscape1mon
An Update on Treatment Strategies for Common Variable Immunodeficiency
Several intravenous and subcutaneous Ig (SCIg) preparations are available either ... approved maximum infusion rate and excipients. [51–53] All these factors may contribute to treatment efficacy ...
KORU Medical partners for Phase III trial in rare kidney disorder
Systems (NASDAQ: KRMD), a medical technology firm with a market capitalization of $194 million, announced a partnership with a global pharmaceutical manufacturer to conduct a Phase III clinical trial.
AFP1mon
Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
The ability to infuse a larger infusion volume is expected to increase ... as compared to weekly or bi-weekly with conventional SCIG treatments. “We are delighted that HYQVIA, approved in ...
The Victoria Advocate23d
IHS Passes Rigorous Audit for World-Wide Distribution of its Insignis™ Infusion System
The Insignis Syringe Infusion System is a robust ... effective for patients requiring subcutaneous immunoglobulin (SCIg) for Primary or Secondary Immune Deficiency and neuromodulation therapies.